首页> 美国卫生研究院文献>Journal of Pain Research >Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits
【2h】

Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits

机译:与非甾体类抗炎药共同处方质子泵抑制剂:风险与益处

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonsteroidal anti-inflammatory drugs (NSAIDs) are often coadministered with proton-pump inhibitors (PPIs) to reduce NSAID-induced gastrointestinal (GI) adverse events. This coadministration is generally regarded as safe, and is included in many of the guidelines on NSAID prescription. However, recent evidence indicates that the GI risks associated with NSAIDs can be potentiated when they are combined with PPIs. This review discusses the GI effects and complications of NSAIDs and how PPIs may potentiate these effects, options for prevention of GI side effects, and appropriate use of PPIs in combination with NSAIDs.
机译:非甾体抗炎药(NSAIDs)通常与质子泵抑制剂(PPIs)共同使用,以减少NSAID诱导的胃肠道(GI)不良事件。这种共同给药通常被认为是安全的,并且被包括在许多NSAID处方指南中。但是,最近的证据表明,与NSAID相关的GI风险与PPI结合可以得到增强。这篇综述讨论了非甾体抗炎药的胃肠道作用和并发症,以及PPI如何增强这些作用,预防GI副作用的选项以及将PPI与NSAID组合使用的适当方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号